NASDAQ: CDTConduit Pharmaceuticals Inc Stock
$3.17+0.07 (+2.26%)
Updated Apr 26, 2024
CDT Price
$3.17
Fair Value Price
$0.05
Market Cap
$234.04M
52 Week Low
$0.95
52 Week High
$25.00
P/E
-317x
P/B
-512.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$535.00k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-16.81
Operating Cash Flow
-$8M
Beta
0.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CDT Overview
Murphy Canyon Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the construction/homebuilding companies and adjacent businesses targeting the real estate space. Murphy Canyon Acquisition was incorporated in 2021 and is headquartered in San Diego, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDT ($3.17) is overvalued by 6,536.56% relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CDT ($3.17) is not significantly undervalued (6,536.56%) relative to our estimate of its Fair Value price of $0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CDT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDT due diligence checks available for Premium users.
Be the first to know about important CDT news, forecast changes, insider trades & much more!
CDT News
Valuation
CDT fair value
Fair Value of CDT stock based on Discounted Cash Flow (DCF)
Price
$3.17
Fair Value
$0.05
Overvalued by
6,536.56%
CDT ($3.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDT ($3.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CDT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-317x
Industry
14.88x
Market
41.14x
CDT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-512.12x
Industry
5.85x
CDT's financial health
Profit margin
Revenue
$0.0
Net Income
$1.8M
Profit Margin
0%
CDT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$7.2M
Liabilities
$7.7M
Debt to equity
-16.81
CDT's short-term assets ($5.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDT's long-term liabilities ($5.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
$497.0k
Financing
-$414.0k
CDT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CDT vs Biotech Stocks
Conduit Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.